• Curative Biotechnology received a USPTO Notice of Allowance for U.S. Patent Application No. 17/642,610 covering topical metformin eye-drop methods.
• Claims cover treatment of retinal degeneration, including age-related macular degeneration, using pharmaceutical compositions formulated for topical ocular delivery.
• Curative holds an exclusive worldwide license to the NEI-developed technology under a patent license agreement with the National Eye Institute.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curative Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607160700PRIMZONEFULLFEED9763301) on July 16, 2026, and is solely responsible for the information contained therein.